Search results for "Assay"

showing 10 items of 2241 documents

Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking

2015

Apigenin is a common dietary flavonoid with considerable cytotoxic activity in vitro and in vivo. Despite many mechanistic studies, less is known about resistance factors hampering apigenin's activity. We investigated the ATP-binding cassette (ABC) transporters BCRP/ABCG2, P-glycoprotein/ABCB1 and its close relative ABCB5. Multidrug-resistant cells overexpressing these ABC transporters were not cross-resistant toward apigenin. Moreover, apigenin inhibited not only P-glycoprotein but also BCRP by increasing cellular uptake of doxorubicin and synergistic inhibition of cell viability in combination with doxorubicin or docetaxel in multidrug-resistant cells. To perform in silico molecular docki…

Cancer ResearchAbcg2Protein ConformationEndocrinology Diabetes and MetabolismClinical BiochemistryATP-binding cassette transporterPharmacologyBiochemistryMicechemistry.chemical_compoundTranscriptional regulationCluster AnalysisImmunology and AllergyApigeninNutrition and DieteticsbiologyABCB5Drug Resistance MultipleNeoplasm ProteinsMolecular Docking SimulationOncologyBiochemistryApigeninMolecular Medicinemedicine.drugIn silicoImmunologyInhibitory Concentration 50Cell Line TumormedicineAnimalsHumansDoxorubicinATP Binding Cassette Transporter Subfamily B Member 1RNA MessengerViability assayMolecular BiologyPharmacologyComputational BiologyPolyphenolsTransporterIn vitroHEK293 CellschemistryDoxorubicinDrug Resistance NeoplasmPharmacogeneticsPoster Presentationbiology.proteinATP-Binding Cassette TransportersThe Journal of Nutritional Biochemistry
researchProduct

Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.

2009

The cancer-testis antigen NY-ESO-1 has been targeted as a tumor-associated antigen by immunotherapeutical strategies, such as cancer vaccines. The prerequisite for a T-cell-based therapy is the induction of T cells capable of recognizing the NY-ESO-1-expressing tumor cells. In this study, we generated human T lymphocytes directed against the immunodominant NY-ESO-1(157-165) epitope known to be naturally presented with HLA-A*0201. We succeeded to isolate autorestricted and allorestricted T lymphocytes with low, intermediate or high avidity TCRs against the NY-ESO-1 peptide. The avidity of the established CTL populations correlated with their capacity of lysing HLA-A2-positive, NY-ESO-1-expre…

Cancer ResearchAdoptive cell transferReceptors Antigen T-Cellchemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent AssayStreptamerBiologyEpitopeAntigenAntigens NeoplasmHLA-A2 AntigenCytotoxic T cellHumansAvidityAntigen PresentationHLA-A AntigensT-cell receptorAntibody-Dependent Cell CytotoxicityMembrane ProteinsT lymphocyteCytotoxicity Tests ImmunologicFlow CytometryPeptide FragmentsNeoplasm ProteinsGenes T-Cell ReceptorOncologyImmunologyProtein MultimerizationT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Inhibition of HSP70: a challenging anti-cancer strategy.

2012

HSP70 is a chaperone that accumulates in the cells after many different stresses promoting cell survival in response to the adverse conditions. In contrast to normal cells, most cancer cells abundantly express HSP70 at the basal level to resist to various insults at different stages of tumorigenesis and during anti-cancer treatment. This cancer cells addiction for HSP70 is the rational for its targeting in cancer therapy. Much effort has been dedicated in the last years for the active search of HSP70 inhibitors. Additionally, the recent clinical trials on highly promising inhibitors of another stress protein, HSP90, showed compensatory increase in HSP70 levels and raised the question of nec…

Cancer ResearchAntineoplastic AgentsApoptosismedicine.disease_cause03 medical and health sciences0302 clinical medicineImmune systemStress PhysiologicalHeat shock proteinNeoplasmsmedicineAutophagyAnimalsHumansHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsMolecular Targeted Therapy030304 developmental biology0303 health sciencesbiologyHsp903. Good healthNeoplasm ProteinsProtein Structure TertiaryClinical trialOncologyApoptosisDrug Resistance Neoplasm030220 oncology & carcinogenesisChaperone (protein)Drug DesignCancer cellImmunologybiology.proteinCancer researchDrug Screening Assays AntitumorCarcinogenesisMolecular ChaperonesCancer letters
researchProduct

Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent …

2008

AbstractColorectal cancer is one of the most common malignancies worldwide. The treatment of advanced colorectal cancer with chemotherapy and radiation has two major problems: development of tumor resistance to therapy and nonspecific toxicity towards normal tissues. Different plant-derived polyphenols show anticancer properties and are pharmacologically safe. In vitro growth of human HT-29 colorectal cancer cells is inhibited (∼56%) by bioavailable concentrations of trans-pterostilbene (trans-3,5-dimethoxy-4′-hydroxystilbene; t-PTER) and quercetin (3,3′,4′,5,6-pentahydroxyflavone; QUER), two structurally related and naturally occurring small polyphenols. I.v. administration of t-PTER and Q…

Cancer ResearchAntioxidantColorectal cancerSp1 Transcription Factormedicine.medical_treatmentDown-RegulationMice NudeAntineoplastic AgentsBiologyAntioxidantsSuperoxide dismutaseMicePhenolsIn vivoGene expressionmedicineAnimalsHumansCell ProliferationFlavonoidsChemotherapySuperoxide DismutaseGene Expression ProfilingNF-kappa BPolyphenolsmedicine.diseaseChemotherapy regimenXenograft Model Antitumor AssaysOxaliplatinUp-RegulationOncologyBiochemistryProto-Oncogene Proteins c-bcl-2Drug Resistance NeoplasmCancer researchbiology.proteinFemaleColorectal NeoplasmsHT29 Cellsmedicine.drugMolecular cancer therapeutics
researchProduct

Selective induction of apoptosis in multidrug resistant HL60R cells by the thiazolobenzoimidazole derivative 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3…

1999

We investigated the antitumour effects of 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3,4-a]benzimidazole (TBZ) a new anti-HIV-1 agent, on human promyelocytic HL60 leukaemia, both a parental and a multidrug resistant form (HL60R). HL60R overexpresses P-glycoprotein and, like HL60, lacks p53 protein expression. HL60 and HL60R show similar levels of Bcl-2 protein. In contrast to the conventional chemotherapeutic agents daunorubicin, etoposide and mitoxantrone, TBZ caused equal or even greater cytotoxicity in HL60R than in HL60, and this result was associated with a more marked induction of apoptosis in the drug resistant cells. The antitumour activity of TBZ occurred in the range of concentrations…

Cancer ResearchBenzimidazoleAnti-HIV AgentsDaunorubicinHL60ApoptosisHL-60 CellsDrug resistancePharmacologychemistry.chemical_compoundmedicineHumansATP Binding Cassette Transporter Subfamily B Member 1CytotoxicityP-glycoproteinbiologyFlow CytometryVirologyDrug Resistance MultipleMultiple drug resistanceThiazolesProto-Oncogene Proteins c-bcl-2OncologychemistryDrug Resistance NeoplasmApoptosisbiology.proteinBenzimidazolesDrug Screening Assays AntitumorTumor Suppressor Protein p53medicine.drugEuropean Journal of Cancer
researchProduct

The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro.

1992

The macrocyclic lactone bryostatin-1 was found to exert in vitro antineoplastic activity against several leukemic cell lines, including human K562 erythroleukemia, HL60 promyelocytic leukemia, REH and MOLT-4 lymphoblastic leukemias, CCRFCEM lymphoma, KG-1 myeloid leukemia, and murine P388 lymphocytic leukemia. No statistically significant difference in sensitivity to bryostatin-1 was found between adriamycin-resistant P388 and K526 subclones and their sensitive counterparts. Freshly explanted clonogenic leukemic cells showed a variable sensitivity to bryostatin-1 in 10/12 tested samples. The IC50 of clonogenic leukemic cells was 4 × 10–3 M bryostatin-1, and that of normal marrow CFU-GM was…

Cancer ResearchBryostatin 1LymphomaHL60Antineoplastic AgentsAntileukemic agent030218 nuclear medicine & medical imaging03 medical and health scienceschemistry.chemical_compoundLactones0302 clinical medicinehemic and lymphatic diseasesmedicineTumor Cells CulturedHumansClonogenic assayTumor Stem Cell AssayLeukemiaChemistryMyeloid leukemiaGeneral Medicinemedicine.diseaseBryostatinsHaematopoiesisLeukemiaOncology030220 oncology & carcinogenesisCancer researchMacrolidesDrug Screening Assays AntitumorK562 cellsTumori
researchProduct

Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.

2018

Primary liver cancer (PLC) ranks among the most lethal solid cancers worldwide due to lack of effective biomarkers for early detection and limited treatment options in advanced stages. Development of primary culture models that closely recapitulate phenotypic and molecular diversities of PLC is urgently needed to improve the patient outcome. Long-term cultures of 7 primary liver cancer cell lines of hepatocellular and cholangiocellular origin were established using defined culture conditions. Morphological and histological characteristics of obtained cell lines and xenograft tumors were analyzed and compared to original tumors. Time course analyses of transcriptomic and genomic changes were…

Cancer ResearchCarcinogenesisDNA Mutational AnalysisPrimary Cell CultureAntineoplastic AgentsDiseaseBiologymedicine.disease_causeTranscriptome03 medical and health sciencesMice0302 clinical medicineCell Line TumormedicineBiomarkers TumorAnimalsHumansPrecision MedicineDrug discoveryGene Expression ProfilingLiver NeoplasmsHigh-Throughput Nucleotide SequencingGenomicsPrecision medicinemedicine.diseasePhenotypeXenograft Model Antitumor AssaysOncologyCell culture030220 oncology & carcinogenesisMutationCancer researchKRASLiver cancerInternational journal of cancer
researchProduct

Downregulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effe…

2001

We investigated the antitumour effects of interleukin 6 (IL-6) on hepatocarcinoma HepG2 cells, endowed with high levels of a mutated, non-degradable, beta-catenin. IL-6 produced minimal growth-inhibitory effects and no apoptosis or gross changes in cell adhesion. Interestingly, however, it caused a consistent decrease in the cytoplasmic levels of wild-type, but not of mutated, beta-catenin protein. There was no effect on E-cadherin or gamma-catenin and a reduction in alpha-catenin occurred only at high concentrations. IL-4, a non-related cytokine, did not modify the content of beta-catenin. IL-6 did not influence beta-catenin mRNA levels. LiCl, a potent inhibitor of Glycogen Synthase Kinase…

Cancer ResearchCarcinoma Hepatocellularmedicine.medical_treatmentBlotting WesternDown-RegulationApoptosisEnzyme-Linked Immunosorbent AssayBiologyDownregulation and upregulationGSK-3Tumor Cells CulturedmedicineHumansRNA MessengerInterleukin 6beta CateninInterleukin 4Interleukin-6Cell growthLiver NeoplasmsWild typeCell biologyCytoskeletal ProteinsCytokineOncologyCateninTrans-ActivatorsCancer researchbiology.proteinEuropean Journal of Cancer
researchProduct

In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player.

2013

Retinoblastoma is the most common intraocular malignancy of childhood. In developing countries, treatment is limited, long-term survival rates are low and current chemotherapy causes significant morbidity to pediatric patients and significantly limits dosing. Therefore there is an urgent need to identify new therapeutic strategies to improve the clinical outcome of patients with retinoblastoma. here, we investigated the effects of two natural compounds okadaic acid (OKa) and parthenolide (PN) on human retinoblastoma Y79 cells. For the first time we showed that OKa/PN combination at subtoxic doses induces potent synergistic apoptotic effects accompanied by lowering in p-akt levels, increasin…

Cancer ResearchCell SurvivalGene ExpressionAntineoplastic AgentsApoptosisBiologychemistry.chemical_compoundSettore BIO/10 - BiochimicaCell Line TumorOkadaic AcidmedicinePTENCytotoxic T cellHumansParthenolideViability assayProtein kinase BCell ShapePharmacologyRetinoblastomaPTEN PhosphohydrolaseRetinoblastomaDrug SynergismProto-Oncogene Proteins c-mdm2Okadaic acidmedicine.diseaseGlutathioneOxidative StressOncologychemistryApoptosisCancer researchbiology.proteinMolecular Medicineretinoblastoma Y79 cells synergistic apoptotic effects oxidative stress natural drugs PTEN/Akt/Mdm2/p53 pathway parthenolide okadaic acid.Drug Screening Assays AntitumorTumor Suppressor Protein p53Reactive Oxygen SpeciesProtein Processing Post-TranslationalProto-Oncogene Proteins c-aktSesquiterpenesResearch PaperCancer biologytherapy
researchProduct

The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy.

2000

Acetaminophen is oxidized by human CYP1A2 to the cytotoxic metabolite N-acetylbenzoquinoneimine (NABQI). Incubation of cells transfected with human CYP1A2 (H1A2 MZ cells) with 4-20 mM acetaminophen for 6 hours at 37 degrees C caused extensive cytotoxicity (cell viability10%). In contrast, nontransfected V79 MZ cells were unaffected (viability95%). By mixing H1A2 MZ cells with V79 MZ cells in various proportions and incubating with 4 mM acetaminophen, it was shown that the NABQI released from H1A2 MZ cells also caused cytotoxicity of bystander cells. Thus, in a mixture containing 5% H1A2 MZ cells, exposure to 4 mM acetaminophen for 6 hours resulted in complete cell killing by 24 hours. A sim…

Cancer ResearchCell SurvivalPharmacologyTransfectionCatalysisCell LineCricetulusCytochrome P-450 CYP1A2CricetinaemedicineTumor Cells CulturedCytotoxic T cellAnimalsHumansProdrugsViability assayCytotoxicityMolecular BiologyAcetaminophenChemistryCYP1A2TransfectionGenetic TherapyProdrugAcetaminophenCell killingMolecular Medicinemedicine.drugCancer gene therapy
researchProduct